Annals of Rehabilitation Medicine

Therapeutic Effect according to Estrogen Dosage on Combined Therapy with Estrogen and Alendronate in Postmenopausal Osteoporosis.: Kim, Ghi Chan , Jeong, Ho Joong , Ha, Ho Sung , Lee, Sang Jin; J Korean Acad Rehabil Med 2006;30(3):247-253.

Abstract
PDF

Objective
To compare the difference of bone mineral density (BMD), biochemical markers, and lipid profiles according to dosage of estrogen on combined therapy with estrogen and alendronate in postmenopausal osteoporosis. Method: We studied 81 women with postmenopausal osteoporosis (T-score＜2.5) from March 2002 to February 2005. Subjects were divided in two groups; Group I (n=36), treated with low dose hormone therapy (HT) (0.3 mg estrogen/1.25 mg MPA (Medroxyprogesterone acetate)) and alendronate, and Group II (n=45), treated with standard dose HT (0.625 mg estrogen/2.5 mg MPA) and alendronate. BMD at the L-spine and femur, osteocalcin, deoxypyridinoline, and lipid profiles were measured at baseline and 1 year after treatment.Results: BMD at the L-spine increased significantly in two groups and BMD at the femur increased but showed no statistical differences. Deoxypyridinoline and osteocalcin decreased significantly in two group. Total cholesterol and LDL (low density lipoprotein) cholesterol decreased significantly in two groups, no significant difference was observed between two groups in BMD, osteocalcin, deoxypyridinoline, and lipid profiles. Conclusion: We concluded that combined therapy with low dose estrogen and alendronate in postmenopausal osteoporosis showed similar therapeutic effect provied by combined therapy of standard dose estrogen and alendronate. (J Korean Acad Rehab Med 2006; 30: 247-253)

1,535 View
8 Download

The Increment of Bone Density in Patients with Spinal Cord Injury after Alendronate Therapy.: Seo, Jeong Hwan , Lee, Roo Ji , Ko, Myoung Hwan , Park, Sung Hee; J Korean Acad Rehabil Med 2005;29(2):187-192.

Abstract
PDF

Objective
The aim of this study was to investigate the changes of bone mineral density (BMD) according to the postinjury duration, walking ability, and to assess the effect of oral alendronate therapy on BMD and biochemical markers in patients with spinal cord injury. Method: Forty-eight subjects with spinal cord injury were enrolled. One tablet of Alend^Ⱂ (10 mg of sodium alendronate) was administered daily for 6 months. After this, all subjects received placebo for 6 months as the same manner. The baseline quantitative assessments of BMD and biochemical bone markers, serum osteocalcin and C-terminal telopeptide of type I collagen (ICTP), were performed before the administration of drug. The follow up assess-ments were performed at 6 and 12 months after drug and placebo administration. Results: The patients treated with oral alendronate showed significantly higher BMD of femur compared with baseline (p＜0.05). Also, ICTP showed significant reduction after alendronate therapy. BMD change rate of alendronate therapy was higher in functional ambulation group compared with wheelchair ambulation group. BMD change rate of alendronate therapy was higher than that of placebo administration. Conclusion: Alendronate therapy may be useful in prevention of loss of BMD after spinal cord injury. (J Korean Acad Rehab Med 2005; 29: 187-192)

1,430 View
5 Download

Changes of Bone Mineral Density, Lipid Profiles, and Biochemical Markers after Combination Therapy of Estrogen and Alendronate in Postmenopausal Osteoporosis.: Kim, Ghi Chan , Jeong, Ho Joong , Chung, Suk Mo , Roh, Kyung Hwan; J Korean Acad Rehabil Med 2002;26(2):208-214.

Abstract
PDF

Objective: To investigate the changes of bone mineral density (BMD), biochemical bone markers, and lipid profiles after combination therapy of continuous hormonal replacement therapy (c-HRT) and alendronate in postmenopausal osteoporosis.

Method: We studied 89 women with postmenopausal osteoporosis (T-score＜2.5) who visited at Department of Rehabilitation Medicine, Kosin Medical Center from August 1999 to March 2001. Subjects were divided into two groups; Group I (n=40), treated with estrogen and alendronate (10 mg/day), and Group II (n=49), treated with estrogen alone. BMD at the lumbar spine and femur, osteocalcin, urine deoxypyridinoline and lipid profiles were measured at baseline and 1-year after treatment.

Results: 1) BMD at the lumbar spine increased significantly

in two groups, and BMD in Group I increased significantly more than that in Group II. But, change of BMD on femoral neck was not significantly different. 2) Biochemical bone markers (osteocalcin and urine deoxypyridinoline) decreased significantly in two groups. 3) Total cholesterol and LDL cholesterol decreased significantly in two groups, but HDL cholesterol and triglyceride showed no significant change in two groups. There was no significant differences between two groups in lipid profiles.

Conclusion: We concluded that combination therapy with c- HRT and alendronate in postmenopausal osteoporosis was more effective than c-HRT, which would not influence on positive effect of estrogen for lipid metabolism. (J Korean Acad Rehab Med 2002; 26: 208-214)

1,438 View
6 Download

Page Path

"Alendronate"

Article category

Keywords

Publication year

Keywords

authors

Publication Year

Funded articles

"Alendronate"

ABOUT

ARTICLE TYPES

BROWSE ARTICLES

AUTHOR INFORMATION